Differential Biliary Adverse Event Signals Among GLP-1 Receptor Agonists: A FAERS Disproportionality Analysis.
Specific GLP-1 diabetes drugs show different risk patterns for gallbladder problems, helping doctors choose safer options for vulnerable patients.
This FAERS disproportionality analysis examined differential biliary adverse event signals across GLP-1 receptor agonist agents, finding agent-specific differences that could inform prescribing decisions for patients at elevated biliary risk. The study adds to real-world safety characterization of a rapidly expanding drug class.
What the study was
- Study design
- Pharmacovigilance disproportionality analysis (FDA FAERS database)
- Population
- GLP-1 RA users in FDA FAERS database
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Dig Dis Sci
Why it surfaced
FAERS analysis of biliary AEs across GLP-1 RA agents; differential findings could have prescribing implications for at-risk patients. Standard safety surveillance contribution.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.